• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Recent Advances in the Study of 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine (CAS: 1211579-06-4) in Chemical Biology and Pharmaceutical Research

The compound 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine (CAS: 1211579-06-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, featuring a piperidine scaffold linked to a brominated pyrazole moiety, exhibits unique chemical properties that make it a promising candidate for drug discovery and development. Recent studies have explored its potential as a building block for novel bioactive molecules, particularly in the context of kinase inhibition and central nervous system (CNS) targeting.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine as a key intermediate in the synthesis of selective kinase inhibitors. The researchers demonstrated that modifications to the piperidine ring and pyrazole bromine position could significantly alter the compound's binding affinity to various kinase targets. Molecular docking studies revealed that the bromine atom plays a crucial role in forming halogen bonds with kinase active sites, suggesting potential applications in cancer therapy.

In neuropharmacology, recent work has focused on the compound's potential as a scaffold for developing sigma receptor ligands. A 2024 preprint on bioRxiv reported that derivatives of 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine showed promising binding affinities to σ1 and σ2 receptors, with potential applications in neurodegenerative diseases and pain management. The study highlighted the compound's ability to cross the blood-brain barrier, a critical feature for CNS-targeting drugs.

Synthetic methodology developments have also advanced significantly. A recent publication in Organic Letters described an improved synthetic route for 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine with higher yields and better purity profiles. The new method utilizes microwave-assisted synthesis, reducing reaction times from hours to minutes while maintaining excellent regioselectivity. This advancement could facilitate broader adoption of the compound in medicinal chemistry programs.

From a safety and toxicology perspective, preliminary studies conducted in 2024 have begun to characterize the compound's pharmacokinetic properties. While showing generally favorable metabolic stability in liver microsome assays, researchers noted that the bromine atom might contribute to potential bioactivation concerns that warrant further investigation. These findings suggest that future structural modifications may be necessary to optimize the compound's drug-like properties.

The pharmaceutical industry has taken notice of these developments, with several companies reportedly including 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine in their fragment-based drug discovery libraries. Its combination of synthetic accessibility, structural diversity potential, and demonstrated biological activity makes it particularly valuable for lead generation programs targeting challenging biological targets.

Looking forward, researchers anticipate that 4-[(4-bromo-1H-pyrazol-1-yl)methyl]piperidine will continue to serve as an important scaffold in medicinal chemistry. Ongoing studies are exploring its application in PROTAC (proteolysis targeting chimera) design, where its ability to form multiple interactions with target proteins could prove particularly valuable. Additionally, computational chemistry approaches are being employed to predict novel derivatives with enhanced pharmacological properties.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)